TN2010000200A1 - Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor - Google Patents

Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor

Info

Publication number: TN2010000200A1
Authority: TN; Tunisia
Prior art keywords: superstructures; arb; nep; blocker; inhibitor
Prior art date: 2007-11-06

Application number

TN2010000200A

Other languages

English (en)

Inventor

Fayoumi Suliman Al

Jiahui Hu

Natrajan Kumaraperumal

Alan Edward Royce

Colleen Ruegger

Erika Aina Zannou

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-06

Filing date

2010-04-30

Publication date

2011-11-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-30 Application filed by Novartis Ag filed Critical Novartis Ag

2011-11-11 Publication of TN2010000200A1 publication Critical patent/TN2010000200A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TN2010000200A 2007-11-06 2010-04-30 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor TN2010000200A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98566807P	2007-11-06	2007-11-06
PCT/US2008/082324 WO2009061713A1 (fr)	2007-11-06	2008-11-04	Compositions pharmaceutiques

Publications (1)

Publication Number	Publication Date
TN2010000200A1 true TN2010000200A1 (en)	2011-11-11

Family

ID=40451030

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000200A TN2010000200A1 (en)	2007-11-06	2010-04-30	Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor

Country Status (33)

Country	Link
US (3)	US20100267786A1 (fr)
EP (4)	EP2217205B1 (fr)
JP (2)	JP5653218B2 (fr)
KR (2)	KR101700062B1 (fr)
CN (2)	CN101848700A (fr)
AR (1)	AR069184A1 (fr)
AU (1)	AU2008324878B2 (fr)
BR (1)	BRPI0823505A2 (fr)
CA (1)	CA2703598C (fr)
CL (1)	CL2008003298A1 (fr)
CY (2)	CY1116280T1 (fr)
DK (3)	DK2217205T3 (fr)
EC (1)	ECSP10010160A (fr)
ES (3)	ES2939163T3 (fr)
FI (1)	FI3067043T3 (fr)
GT (1)	GT201000131A (fr)
HR (3)	HRP20150459T1 (fr)
HU (2)	HUE028866T2 (fr)
IL (3)	IL262990B2 (fr)
JO (1)	JOP20080499B1 (fr)
MA (1)	MA31797B1 (fr)
MX (1)	MX2010004930A (fr)
MY (1)	MY153730A (fr)
NZ (1)	NZ584686A (fr)
PE (2)	PE20141072A1 (fr)
PL (3)	PL3067043T3 (fr)
PT (3)	PT2295035T (fr)
RU (1)	RU2493844C3 (fr)
SG (1)	SG185951A1 (fr)
SI (3)	SI3067043T1 (fr)
TN (1)	TN2010000200A1 (fr)
TW (1)	TWI484982B (fr)
WO (1)	WO2009061713A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2939163T3 (es)	2007-11-06	2023-04-19	Novartis Ag	Composiciones farmacéuticas basadas en superestructuras de antagonista/bloqueante del receptor de angiotensina (ARB) e inhibidor de la endopeptidasa neutra (NEP)
JP5466759B2 (ja)	2009-05-28	2014-04-09	ノバルティスアーゲー	ネプリライシン阻害剤としての置換アミノ酪酸誘導体
ES2523734T3 (es)	2009-05-28	2014-12-01	Novartis Ag	Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
PH12013500231A1 (en)	2010-08-24	2017-08-09	Novartis Ag	Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP3943084A1 (fr) *	2012-08-24	2022-01-26	Novartis AG	Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MX367525B (es)	2013-02-14	2019-08-26	Novartis Ag	Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep).
JP6301371B2 (ja)	2013-02-14	2018-04-11	ノバルティスアーゲー	インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体
JP2016530282A (ja) *	2013-08-26	2016-09-29	ノバルティスアーゲー	新規使用
ES2767084T3 (es)	2013-08-26	2020-06-16	Novartis Ag	Nuevo uso
CN106795099B (zh) *	2014-04-10	2019-11-26	南京奥昭生物科技有限公司	用于治疗高血压和心血管疾病的前药和组合物
CN105461647B (zh) *	2014-09-28	2018-06-29	四川海思科制药有限公司	缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
WO2016049663A1 (fr)	2014-12-08	2016-03-31	Crystal Pharmatech Inc.	Formes cristallines de complexe supramoléculaire de trisodium comprenant du valsartan et ahu-377 ainsi que procédés associés
CN104473938B (zh) *	2014-12-30	2017-06-09	北京瑞都医药科技有限公司	一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) *	2015-04-19	2015-08-12	浙江巨泰药业有限公司	一种抗心衰药物组合物及其制备方法
HUE071910T2 (hu)	2015-05-11	2025-10-28	Novartis Ag	Szakubitril-valzartán adagolási rend krónikus szisztolés szívelégtelenség kezelésére
WO2016193883A1 (fr)	2015-05-29	2016-12-08	Novartis Ag	Sacubitril et valsartan pour le traitement d'une maladie métabolique
CN106309388A (zh) *	2015-06-30	2017-01-11	深圳信立泰药业股份有限公司	一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (fr)	2015-07-08	2017-01-12	Novartis Ag	Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
CN105997993B (zh) *	2015-07-11	2018-03-30	麦丽芳	一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) *	2015-07-11	2016-10-12	凌莉	一种固体口服型制剂及其制备方法
CN106176725A (zh) *	2015-07-11	2016-12-07	凌莉	一种提高稳定性的药物组合物及其制备方法和用途
CN106176724A (zh) *	2015-07-11	2016-12-07	凌莉	一种稳定的固体药物组合物及其制备方法
CN106176723A (zh) *	2015-07-11	2016-12-07	凌莉	一种固体药物组合物及其制备方法
CN106074421A (zh) *	2015-07-11	2016-11-09	凌莉	一种提高稳定性的药物组合物
WO2017012600A1 (fr)	2015-07-20	2017-01-26	Zentiva, K.S.	Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
CN106397249A (zh) *	2015-08-03	2017-02-15	深圳信立泰药业股份有限公司	一种高稳定性lcz696结晶粉末及其制备方法
JP6598985B2 (ja)	2015-08-28	2019-10-30	ノバルティスアーゲー	新規の使用
WO2017037596A1 (fr) *	2015-08-28	2017-03-09	Dr. Reddy's Laboratories Limited	Dispersion solide amorphe de lcz-696
CN106580908A (zh) *	2015-10-16	2017-04-26	深圳信立泰药业股份有限公司	一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) *	2015-11-09	2017-03-22	成都苑东生物制药股份有限公司	一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (fr) *	2015-11-20	2017-05-26	Lupin Limited	Complexe de sacubitril-valsartan amorphe et son procédé de préparation
CN105330609B (zh) *	2015-12-07	2017-12-22	南京正大天晴制药有限公司	一种制备lcz696的方法
CN105935358B (zh) *	2015-12-18	2019-06-07	重庆两江药物研发中心有限公司	一种沙库比曲缬沙坦缓释剂及其制备方法
CN105929031B (zh) *	2015-12-18	2018-08-21	重庆两江药物研发中心有限公司	一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN106905253B (zh) *	2015-12-23	2020-01-03	正大天晴药业集团股份有限公司	一种超分子复合物的结晶
JP6810152B2 (ja)	2016-02-03	2021-01-06	ノバルティスアーゲー	サクビトリルおよびバルサルタンの組合せの新規使用
US10722471B2 (en)	2016-02-03	2020-07-28	Novartis Ag	Galenic formulations of organic compounds
CN105748420B (zh) *	2016-03-04	2018-11-06	山东省药学科学院	一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) *	2016-06-12	2016-08-31	佛山市腾瑞医药科技有限公司	一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (fr)	2016-10-13	2018-04-19	Mylan Laboratories Limited	Dispersions solides de sacubitril/valsartan trisodique et procédé de leur préparation
EP3600255B1 (fr) *	2017-03-31	2021-07-07	Alfred E. Tiefenbacher (GmbH & Co. KG)	Extrudat thermofusible stable contenant du valsartan et du sacubitril
WO2018178295A1 (fr)	2017-03-31	2018-10-04	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Extrudat thermofusible stable contenant du valsartan et du sacubitril
WO2018211479A1 (fr) *	2017-05-19	2018-11-22	Lupin Limited	Compositions stabilisées d'inhibiteurs de l'angiotensine ii et d'inhibiteurs de l'endopeptidase neutre, et leur procédé de préparation
WO2019008485A1 (fr)	2017-07-06	2019-01-10	Mankind Pharma Ltd	Composition pharmaceutique à dose fixe à base de valsartan et de sacubitril
EA202090398A1 (ru)	2017-07-28	2020-05-15	Синтон Б.В.	Фармацевтическая композиция, включающая сакубитрил и валсартан
US20200276129A1 (en)	2017-10-13	2020-09-03	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Tablet containing valsartan and sacubitril
WO2019180735A1 (fr) *	2018-03-19	2019-09-26	Natco Pharma Limited	Compositions pharmaceutiques stables comprenant un complexe de sacubitril-valsartan
US11877576B2 (en)	2018-06-22	2024-01-23	Ideaz, Llc	Diphenyl tablets and methods of preparing the same
US20210177803A1 (en)	2018-08-23	2021-06-17	Novartis Ag	New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Nouvelles combinaisons de médicaments
EP3766484B1 (fr)	2019-07-19	2021-08-25	Zentiva, K.S.	Forme posologique pharmaceutique solide comprenant du valsartan et du sacubitril
KR102545274B1 (ko)	2020-02-26	2023-06-20	에리슨제약(주)	사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko)	2020-03-27	2021-10-07	주식회사 유영제약	고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko)	2020-05-12	2021-11-19	에리슨제약(주)	사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko)	2020-12-24	2022-07-01	주식회사 보령	사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko)	2021-01-20	2023-01-10	주식회사 대웅제약	Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US607893A (en)		1898-07-26		Automatic switch-operating machine
US608220A (en)		1898-08-02		Mechanical movement
US607355A (en)		1898-07-12		Carrier for bicycles
US735093A (en)	1903-01-31	1903-08-04	Oscar Greenwald	Elevator-cable guard.
GB9613470D0 (en)	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
US6558699B2 (en) *	1997-11-17	2003-05-06	Smithkline Beecham Corporation	High drug load immediate and modified release oral dosage formulations and processes for their manufacture
HUP0004407A3 (en) *	1997-11-17	2002-03-28	Smithkline Beecham Corp	Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture
ATE302012T1 (de) *	1998-06-17	2005-09-15	Bristol Myers Squibb Co	Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
DE69935249T2 (de) *	1998-12-23	2007-10-31	Novartis Ag	Verwendung von at-1 rezeptorantagonisten oder at-2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
CA2415962C (fr)	2000-07-19	2010-07-06	Novartis Ag	Sels de valsartan
DE60315795T2 (de) *	2002-01-17	2008-06-05	Novartis Ag	Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
US7468390B2 (en) *	2002-01-17	2008-12-23	Novartis Ag	Methods of treatment and pharmaceutical composition
JP3751287B2 (ja) *	2002-03-27	2006-03-01	バイエル薬品株式会社	小型化されたニフェジピン有核錠剤
WO2003089417A1 (fr)	2002-04-15	2003-10-30	Dr. Reddy's Laboratories Limited	Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
CA2519490A1 (fr)	2003-03-17	2004-09-30	Teva Pharmaceutical Industries Ltd	Formes polymorphes de valsartan
CA2532450C (fr) *	2003-07-16	2012-09-11	Boehringer Ingelheim International Gmbh	Combinaisons de chlorthalidone
GB0402262D0 (en) *	2004-02-02	2004-03-10	Novartis Ag	Process for the manufacture of organic compounds
GT200600371A (es)	2005-08-17	2007-03-21		Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
JP2009513622A (ja) *	2005-10-27	2009-04-02	ルピン・リミテッド	ロサルタンの医薬製剤
WO2007052307A2 (fr)	2005-10-31	2007-05-10	Lupin Limited	Formes posologiques solides orales stables de valsartan
CA2628793C (fr)	2005-11-07	2015-01-27	Stryker Corporation	Appareil de manipulation de patients comprenant une signalisation locale, un ajustement de l'angle de fowler a l'aide d'une seule touche et une configuration d'alarme d'alimentation
AU2006311723A1 (en)	2005-11-08	2007-05-18	Novartis Ag	Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (fr) *	2006-09-04	2008-03-12	Novartis AG	Composition contenant un antagoniste des récepteurs de l'angiotensine II
ES2939163T3 (es)	2007-11-06	2023-04-19	Novartis Ag	Composiciones farmacéuticas basadas en superestructuras de antagonista/bloqueante del receptor de angiotensina (ARB) e inhibidor de la endopeptidasa neutra (NEP)

2008
- 2008-11-04 ES ES16157767T patent/ES2939163T3/es active Active
- 2008-11-04 DK DK08848154.4T patent/DK2217205T3/en active
- 2008-11-04 US US12/741,251 patent/US20100267786A1/en not_active Abandoned
- 2008-11-04 HR HRP20150459TT patent/HRP20150459T1/hr unknown
- 2008-11-04 MY MYPI2010001722A patent/MY153730A/en unknown
- 2008-11-04 ES ES10173506.6T patent/ES2587336T3/es active Active
- 2008-11-04 EP EP08848154.4A patent/EP2217205B1/fr not_active Revoked
- 2008-11-04 CN CN200880114940A patent/CN101848700A/zh active Pending
- 2008-11-04 AU AU2008324878A patent/AU2008324878B2/en active Active
- 2008-11-04 DK DK16157767.1T patent/DK3067043T3/da active
- 2008-11-04 KR KR1020157033633A patent/KR101700062B1/ko not_active Ceased
- 2008-11-04 PL PL16157767.1T patent/PL3067043T3/pl unknown
- 2008-11-04 IL IL262990A patent/IL262990B2/en unknown
- 2008-11-04 ES ES08848154.4T patent/ES2536514T3/es active Active
- 2008-11-04 KR KR1020107009852A patent/KR101589317B1/ko not_active Ceased
- 2008-11-04 PT PT101735066T patent/PT2295035T/pt unknown
- 2008-11-04 CA CA2703598A patent/CA2703598C/fr active Active
- 2008-11-04 JP JP2010533185A patent/JP5653218B2/ja active Active
- 2008-11-04 PE PE2013002393A patent/PE20141072A1/es active IP Right Grant
- 2008-11-04 HU HUE10173506A patent/HUE028866T2/en unknown
- 2008-11-04 EP EP22200982.1A patent/EP4186491A1/fr active Pending
- 2008-11-04 JO JOP/2008/0499A patent/JOP20080499B1/ar active
- 2008-11-04 EP EP10173506.6A patent/EP2295035B1/fr not_active Revoked
- 2008-11-04 FI FIEP16157767.1T patent/FI3067043T3/fi active
- 2008-11-04 PL PL10173506.6T patent/PL2295035T3/pl unknown
- 2008-11-04 SG SG2012081394A patent/SG185951A1/en unknown
- 2008-11-04 DK DK10173506.6T patent/DK2295035T3/en active
- 2008-11-04 BR BRPI0823505-8A patent/BRPI0823505A2/pt not_active Application Discontinuation
- 2008-11-04 PE PE2008001886A patent/PE20091390A1/es not_active Application Discontinuation
- 2008-11-04 AR ARP080104826A patent/AR069184A1/es not_active Application Discontinuation
- 2008-11-04 SI SI200832204T patent/SI3067043T1/sl unknown
- 2008-11-04 PL PL08848154T patent/PL2217205T3/pl unknown
- 2008-11-04 HR HRP20230178TT patent/HRP20230178T3/hr unknown
- 2008-11-04 HU HUE16157767A patent/HUE061321T2/hu unknown
- 2008-11-04 PT PT88481544T patent/PT2217205E/pt unknown
- 2008-11-04 NZ NZ584686A patent/NZ584686A/xx unknown
- 2008-11-04 RU RU2010123027A patent/RU2493844C3/ru active
- 2008-11-04 EP EP16157767.1A patent/EP3067043B1/fr active Active
- 2008-11-04 SI SI200831654A patent/SI2295035T1/sl unknown
- 2008-11-04 SI SI200831427T patent/SI2217205T1/sl unknown
- 2008-11-04 PT PT161577671T patent/PT3067043T/pt unknown
- 2008-11-04 WO PCT/US2008/082324 patent/WO2009061713A1/fr not_active Ceased
- 2008-11-04 CN CN2013101540642A patent/CN103251587A/zh active Pending
- 2008-11-04 MX MX2010004930A patent/MX2010004930A/es active IP Right Grant
- 2008-11-05 CL CL2008003298A patent/CL2008003298A1/es unknown
- 2008-11-05 TW TW097142724A patent/TWI484982B/zh active
2010
- 2010-04-19 IL IL205208A patent/IL205208A/en active IP Right Grant
- 2010-04-30 MA MA32803A patent/MA31797B1/fr unknown
- 2010-04-30 TN TN2010000200A patent/TN2010000200A1/fr unknown
- 2010-05-05 GT GT201000131A patent/GT201000131A/es unknown
- 2010-05-06 EC EC2010010160A patent/ECSP10010160A/es unknown
2014
- 2014-08-12 JP JP2014164022A patent/JP2015038069A/ja not_active Withdrawn
2015
- 2015-05-14 CY CY20151100426T patent/CY1116280T1/el unknown
2016
- 2016-08-02 HR HRP20160988TT patent/HRP20160988T1/hr unknown
- 2016-08-08 CY CY20161100778T patent/CY1117883T1/el unknown
2017
- 2017-01-03 IL IL249922A patent/IL249922A0/en unknown
2020
- 2020-12-02 US US17/109,716 patent/US20210085631A1/en not_active Abandoned
2023
- 2023-05-09 US US18/314,745 patent/US20240115536A1/en active Pending

Also Published As

Publication number	Publication date
SI3067043T1 (sl)	2023-04-28
PT2217205E (pt)	2015-06-08
PL3067043T3 (pl)	2023-05-08
EP2217205A1 (fr)	2010-08-18
MA31797B1 (fr)	2010-10-01
SI2295035T1 (sl)	2016-09-30
CL2008003298A1 (es)	2009-06-26
CN101848700A (zh)	2010-09-29
MY153730A (en)	2015-03-13
EP4186491A1 (fr)	2023-05-31
IL249922A0 (en)	2017-03-30
ES2939163T3 (es)	2023-04-19
CY1116280T1 (el)	2017-03-15
IL262990A (en)	2018-12-31
US20100267786A1 (en)	2010-10-21
DK3067043T3 (da)	2023-02-27
PT3067043T (pt)	2023-03-01
IL262990B1 (en)	2023-06-01
SI2217205T1 (sl)	2015-10-30
EP2295035B1 (fr)	2016-05-18
KR101700062B1 (ko)	2017-01-26
HRP20150459T1 (hr)	2015-07-17
SG185951A1 (en)	2012-12-28
EP3067043A1 (fr)	2016-09-14
IL262990B2 (en)	2023-10-01
JP2015038069A (ja)	2015-02-26
BRPI0823505A2 (pt)	2015-06-16
HRP20160988T1 (hr)	2016-10-07
CA2703598A1 (fr)	2009-05-14
HUE061321T2 (hu)	2023-06-28
FI3067043T3 (fi)	2023-03-18
EP2295035A2 (fr)	2011-03-16
HRP20230178T3 (hr)	2023-03-31
GT201000131A (es)	2012-04-30
ES2536514T3 (es)	2015-05-26
NZ584686A (en)	2013-03-28
EP2295035A3 (fr)	2012-08-08
CA2703598C (fr)	2016-08-09
EP3067043B1 (fr)	2022-11-30
HK1224195A1 (en)	2017-08-18
RU2493844C3 (ru)	2017-07-05
US20240115536A1 (en)	2024-04-11
PL2217205T3 (pl)	2015-07-31
DK2295035T3 (en)	2016-08-29
CY1117883T1 (el)	2017-05-17
IL205208A0 (en)	2010-12-30
KR101589317B1 (ko)	2016-01-28
JP2011503082A (ja)	2011-01-27
PE20091390A1 (es)	2009-10-13
JOP20080499B1 (ar)	2022-09-15
RU2493844C2 (ru)	2013-09-27
HK1143529A1 (en)	2011-01-07
CN103251587A (zh)	2013-08-21
IL205208A (en)	2017-01-31
PE20141072A1 (es)	2014-09-10
ECSP10010160A (es)	2010-06-29
AR069184A1 (es)	2010-01-06
KR20100085087A (ko)	2010-07-28
EP2217205B1 (fr)	2015-03-04
HK1149721A1 (en)	2011-10-14
TWI484982B (zh)	2015-05-21
MX2010004930A (es)	2010-05-27
WO2009061713A1 (fr)	2009-05-14
KR101700062B9 (ko)	2022-11-23
KR20150139624A (ko)	2015-12-11
ES2587336T3 (es)	2016-10-24
PL2295035T3 (pl)	2016-11-30
DK2217205T3 (en)	2015-05-11
HUE028866T2 (en)	2017-01-30
AU2008324878B2 (en)	2013-04-18
AU2008324878A1 (en)	2009-05-14
JP5653218B2 (ja)	2015-01-14
US20210085631A1 (en)	2021-03-25
TW200936183A (en)	2009-09-01
KR101589317B9 (ko)	2022-11-23
RU2010123027A (ru)	2011-12-20
PT2295035T (pt)	2016-08-22

Publication	Publication Date	Title
TN2010000200A1 (en)	2011-11-11	Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
MX343358B (es)	2016-11-03	Tabletas de acetato de ulipristal.
DK1951232T3 (da)	2013-05-06	Fremgangsmåder til at reducere alkohol-induceret dosisdumpning for orale opioide doseringsformer med forsinket frigivelse
IL184027A (en)	2014-11-30	Trisodium compound [3 - ((1s, 3r) -1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate (s) - 3-methyl-2-pentanoyl {"2 - (tetrazole) (5-yl) biphenyl-4-ylmethyl} amino) butyrate] The hypanthate hydrate, its pharmaceutical preparations, its method of preparation and its use in the preparation of drugs
PH12013501341A1 (en)	2014-08-27	Morphinan compounds
CO6440564A2 (es)	2012-05-15	Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
TN2010000011A1 (en)	2011-09-26	Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
ZA200806778B (en)	2009-11-25	N-Hydroxyacrylamide compounds
GR20050100466A (el)	2007-04-25	Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
UA95274C2 (ru)	2011-07-25	Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
ZA200804734B (en)	2009-11-25	Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
GB0616703D0 (en)	2006-10-04	Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
GB0612326D0 (en)	2006-08-02	Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
CO6270299A2 (es)	2011-04-20	Composiciones farmaceuticas de accion doble basadas en super estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidores de endopeptidasa neutra (nep)
GR1006875B (el)	2010-07-12	Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
MX2010009500A (es)	2010-09-24	Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones.
TH123683A (th)	2013-05-23	องค์ประกอบทางเภสัชกรรมซึ่งออกฤทธิ์แบบคู่บนพื้นฐานของโครงสร้างส่วนบนของแองจิโอเทน ซินรีเซพเตอร์แอนตาโกนิสต์/ตัวขัดขวาง (arb) และสารยับยั้งเอนโดเปปติเดสที่เป็นกลาง (nep)
WO2009076983A3 (fr)	2009-11-12	Composition pharmaceutique améliorée contenant un agoniste dopaminergique non ergoté et procédé de préparation de celle-ci
UA52334U (ru)	2010-08-25	Фармацевтическая композиция на основе парацетамола и диклофенака натрия
WO2006092732A3 (fr)	2007-03-29	Forme posologique solide stable d’un agent antihypertenseur
UA93689C2 (ru)	2011-03-10	Фармацевтическая композиция ингибиторов дипептидилпептидазы